Skip to main content

Envista Holdings Corporation (NVST) Stock Analysis

Oversold Bounce setup

HoldModerate Confidence

Healthcare · Medical Instruments & Supplies

Hold if already holding. Not a fresh buy at $23.05, but acceptable to hold if already in. Reason: Negative momentum.

Envista Holdings is a global dental products company with $2.7B in 2025 sales through Specialty Products & Technologies (Nobel Biocare implants, Ormco orthodontics; 64% of sales) and Equipment & Consumables (DEXIS imaging, Kerr materials; 36%). Revenue comes from dentists, DSOs,... Read more

$23.05+12.7% A.UpsideScore 6.2/10#2 of 25 Medical Instruments & Supplies
QualityF-score9 / 9FCF yield5.74%
Stop $21.87Target $25.97(analyst − 13%)A.R:R 1.3:1
Analyst target$29.85+29.5%13 analysts
$25.97our TP
$23.05price
$29.85mean
$21
$35

Hold if already holding. Not a fresh buy at $23.05, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Val7.1Qual5.6Grw8.1Mom2.9Sent6.9Ins5.0Peer5.1Tech7.8Risk6.26.2OVERALL

Recent Developments — Envista Holdings Corporation

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Attractive valuation
Risks
Negative momentum

Key Metrics

P/E (TTM)56.5
P/E (Fwd)14.8
Mkt Cap$3.8B
EV/EBITDA11.2
Profit Mgn2.4%
ROE2.2%
Rev Growth14.4%
Beta0.93
DividendNone
Rating analysts21

Quality Signals

Piotroski F9/9MoatNarrow

Options Flow

P/C0.63bullish
IV48%normal

Concentration Risks(10-K Item 1A)

  • MEDIUMCustomerHenry Schein12%
    10-K Item 1: 'One customer, Henry Schein, Inc. ("Henry Schein"), accounted for approximately 12% of our sales for 2025 and 10% of our sales for 2024 and 2023'
  • LOWGeographicChina7.0%
    10-K Item 1A: 'we generate approximately 7% of our annual sales from China'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
2.2
Rsi
3.0
Volume
8.1
Capitulation risk (RSI 28, below 200MA)Volume distribution (falling OBV)Below 200-MA but MA still rising (+4.0%/30d) — pullback in uptrend, not confirmed weakness
GatesMomentum 2.9<4.5A.R:R 1.3 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEAROversold BounceSuitability: Aggressive
RSI
28 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $22.55Resistance $29.52

Price Targets

$22
$26
A.Upside+12.7%
A.R:R1.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 2.9/10 — below 4.5 minimum
! Reward/Risk 1.3:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-05 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NVST stock a buy right now?

Hold if already holding. Not a fresh buy at $23.05, but acceptable to hold if already in. Reason: Negative momentum. Chart setup: Oversold RSI 28, near Bollinger lower, volume surge. Maintain position. Not compelling to add more. Target $25.97 (+12.7%), stop $21.87 (−5.4%), A.R:R 1.3:1. Score 6.2/10, moderate confidence.

What is the NVST stock price target?

Take-profit target: $25.97 (+12.7% upside). Target $25.97 (+12.7%), stop $21.87 (−5.4%), A.R:R 1.3:1. Stop-loss: $21.87.

What are the risks of investing in NVST?

Negative momentum.

Is NVST overvalued or undervalued?

Envista Holdings Corporation trades at a P/E of 56.5 (forward 14.8). TrendMatrix value score: 7.1/10. Verdict: Hold.

What do analysts say about NVST?

21 analysts cover NVST with a consensus score of 3.9/5. Average price target: $30.

What does Envista Holdings Corporation do?Envista Holdings is a global dental products company with $2.7B in 2025 sales through Specialty Products & Technologies...

Envista Holdings is a global dental products company with $2.7B in 2025 sales through Specialty Products & Technologies (Nobel Biocare implants, Ormco orthodontics; 64% of sales) and Equipment & Consumables (DEXIS imaging, Kerr materials; 36%). Revenue comes from dentists, DSOs, and dental labs in 130+ countries; 51% North America and 49% international.

Related stocks: RMD (ResMed Inc.) · WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · TFX (Teleflex Incorporated) · LMAT (LeMaitre Vascular, Inc.)